title: Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?
abstract: Intravenous immunoglobulins (IVIg) are effective for treating chronic inflammatory demyelinating polyneuropathy (CIDP), although treatment needs are variable and need to be individualized. Dose and frequency requirements are not currently predictable in advance. In Guillain-Barré syndrome, IVIg interpatient pharmacokinetic variations have been demonstrated in relation to clinical outcome. We studied 15 patients with CIDP following two routine courses of IVIg. IgG levels were assessed pretreatment and 14 days post-treatment. Best clinical response (BCR) was ascertained in each case, predefined, according to individual patients' circumstances, on the 10 m walk, or MRC sum score, or Jamar grip dynamometry. Correlations between IgG level variations, doses administered, weight, body mass index, BCR and infusion interval were determined. Postinfusion rise in IgG levels were correlated in individual patients (p = 0.005), but interpatient variability was high. No correlations were ascertained between IgG level variation and weight, body mass index, BCR, total dose of IVIg administered, or dose of IVIg administered per kilogram per week. There were significant correlations between total dose administered and post-infusion IgG level at 14 days (p = 0.004) and between infusion interval and mean rise in IgG level (p = 0.001) These findings suggest significant variability in IgG metabolism between patients, unrelated to minimal effective dose administered, weight, body mass index or degree of functional improvement. Required frequency of IVIg infusions may, however, importantly relate to patient-specific post-infusion rise in IgG levels hence possibly explaining inter-patient differences in treatment frequency needs. IgG level monitoring may be helpful in establishing optimum treatment regimens in individual cases.
authors: Neuromuscular Clinic, Department of Neurology, University Hospitals of Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK. Yusuf.Rajabally@uhb.nhs.uk
authors: Yusuf A
authors: YA
authors: Rajabally
authors: Siew L
authors: SL
authors: Wong
authors: David A
authors: DA
authors: Kearney
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D001835:Body Weight; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000378:metabolism* / Q000628:therapy*; D011446:Prospective Studies
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous
references: J Peripher Nerv Syst. 2011 Jun;16 Suppl 1:38-40
references: 21696496
references: J Neurol Neurosurg Psychiatry. 1999 May;66(5):677-80
references: 10209187
references: J Peripher Nerv Syst. 2006 Dec;11(4):325-9
references: 17117941
references: J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):859-61
references: 23538070
references: Muscle Nerve. 2009 Apr;39(4):432-8
references: 19260065
references: Cochrane Database Syst Rev. 2010 Jun 16;(6):CD002063
references: 20556755
references: Ann Neurol. 2009 Nov;66(5):597-603
references: 19938102
references: JAMA. 2004 May 19;291(19):2367-75
references: 15150209
references: Neurology. 2011 Jan 25;76(4):337-45
references: 21263135
references: Curr Neuropharmacol. 2009 Dec;7(4):337-42
references: 20514213
references: Eur J Neurol. 2010 Mar;17(3):356-63
references: 20456730